Nemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology ...

Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic ...

Switzerland’s Galderma today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic ...

Galderma, the pure-play dermatology category leader, is pioneering new research into the impact of medication-driven weight ...

Bellatox Boutique Photo Julie Bella Robbins Photo Bellatox Boutique Wins Top Injector Practice and Top 1% Galderma Account in the Ae ...

ZUG, Switzerland, January 31, 2025--Galderma (SWX:GALD), the pure-play dermatology category leader, announced today results from its new phase IIIb RELAX clinical trial demonstrating the rapid ...

RBC analysts highlighted potential risks for Galderma stock due to newly imposed 25% tariffs on imports from Canada by the ...

Ad hoc announcement pursuant to Art. 53 LR This approval from the European Commission is based on robust results from the phase III OLYMPIA and ...

Single dose relabotulinumtoxinA demonstrated rapid onset, long-lasting duration of aesthetic efficacy and high patient ...

Dermatology specialist Galderma has claimed a second FDA approval for IL-31 inhibitor Nemluvio, adding atopic dermatitis to its label. Nemluvio (nemolizumab) – which was approved by the FDA in ...

L’Oréal just announced it acquired a 10% stake in Galderma, characterized as a “pure play dermatology leader” in injectibles with Botox-competitor Dysport, and Restylane filler brands.